This research investigates how antiviral drug resistance develops by examining structural changes in viral proteins. Using protein crystallography, it identified why SARS-CoV-2 mutations prevent Paxlovid binding and discovered two compounds capable of inhibiting resistant viruses. The findings could guide development of more effective antivirals against future drug-resistant viral infections.

This research develops “nanozymes,” nanoparticle-based catalysts that activate cancer drugs directly at tumor sites. Instead of carrying large amounts of chemotherapy drugs, nanozymes locally trigger inactive drugs into their active form only within cancer tissue. Early mouse studies show effective tumor destruction with significantly reduced side effects compared to conventional chemotherapy.

Using a Twilight analogy, this research explains antibiotic-resistant bacteria as “vampires” protected by membranes. By crystallizing membrane proteins and analyzing them with X-ray techniques, the study reveals their structure and function. This enables precise drug design to block these proteins, potentially overcoming antibiotic resistance and targeting harmful bacteria more effectively.

This research develops small-molecule treatments for chikungunya virus using a lock-and-key approach targeting viral proteins. A key challenge—molecular orientation (enantiomers)—was addressed with a new synthesis method producing over 95% effective molecules. The optimized compound, BDGR-651, shows promise as a future antiviral treatment for this debilitating disease.

This project uses virtual reality to turn drug design into a spatial puzzle game. By fitting molecular “drug” shapes into protein grooves—much like Tetris—players can exploit human spatial intuition to explore new treatments. Using Nano Simbox software, VR proved over ten times more effective than other platforms for complex molecular tasks.